{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-291327","form_type":"8-K","ticker":null,"cik":"0001501756","company_name":"Adverum Biotechnologies, Inc.","filed_at":"2025-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.572612+00:00","generated_at":"2026-05-16T17:37:06.542115+00:00","sec_items":["1.02","2.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adverum terminates Durham lease, issues $7.4M note; Phase 3 ARTEMIS fully enrolled (284 patients)","bullets":["Terminated lease at 14 TW Alexander Drive, Durham, NC effective Nov 19, 2025; pays $0.1M cash and releases $7.4M promissory note from escrow.","Promissory note matures Jan 2031 or earlier if $150M annual revenue/royalties from Ixo-vec; accelerates upon change of control.","Completed target enrollment of 284 patients in pivotal Phase 3 ARTEMIS trial on Nov 19, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-291327","json":"https://secwatch.observer/filing/0001193125-25-291327.json","markdown":"https://secwatch.observer/filing/0001193125-25-291327.md","text":"https://secwatch.observer/filing/0001193125-25-291327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501756/000119312525291327/0001193125-25-291327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501756/000119312525291327/d88122d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:37:06.542115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b68b709d5d8a15105afa38c20ffde188f9c6b83","claim":"Adverum Biotechnologies, Inc. terminated Original Lease with ARE-NC Region No. 21 LLC valued at $0.1 million (effective 2025-11-19).","evidence_excerpt":"On November 20, 2025, ARE-NC Region No. 21 LLC, a Delaware limited liability company (the “Landlord”), delivered to Adverum Biotechnologies, Inc. (the “Company”) and Adverum NC, LLC, a notice of termination (the “Termination Notice”) of that certain Lease Agreement, dated January 8, 2021, as amended (the “Original Lease”), for the Company’s premises located at 14 TW Alexander Drive, Durham, North Carolina. Pursuant to the Notice, the Original Lease was terminated as of November 19, 2025.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501756/000119312525291327/0001193125-25-291327-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"ARE-NC Region No. 21 LLC"},{"label":"Value","value":"$0.1 million"},{"label":"Effective","value":"2025-11-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}